European Respiratory Journal 2019; DOI: 10.1183/13993003.02003-2018
David A. Jolliffe, Davaasambuu Ganmaa, Christian Wejse, Rubhana Raqib, Md. Ahsanul Haq, Nawal Salahuddin, Peter K. Daley, Anna P. Ralph, Thomas R. Ziegler, Adrian R. Martineau
- TB not treated by average daily 10,000 IU of vitamin D (previous RCTs disagree) – RCT Sept 2017
- Tuberculosis recovery speeded up by single 450,000 IU dose of vitamin D – RCT Jan 2017
- Tuberculosis treatment greatly helped by injection of 200,000 IU of vitamin D – RCT April 2016
- Tuberculosis -100 percent cure rate with 10,000 IU of vitamin D daily – RCT 2006
- Tuberculosis not treated by lots of vitamin D for 16 weeks – RCT Sept 2015
- Every TB patient benefited from 2 doses of 600,000 IU of vitamin D – RCT Jan 2013
- TB treatment helped with Vitamin D – RCT Sept 2012
- Probability of getting TB reduced 60 percent with just 800 IU of vitamin D – RCT Aug 2012
- Overview Tuberculosis and Vitamin D
- Evaluating the vitamin D evidence - Heaney Dec 2010
- Tuberculosis still associated with low vitamin D – 12th meta-analysis June 2021
- Tuberculosis 3X more likely if less than 12 ng of Vitamin D - meta-analysis Sept 2019
- Tuberculosis increased risk if poor Vitamin D receptor varies by race – meta-analysis Feb 2019
- Tuberculosis (multi-drug resistant) was 13.4 X more likely to be quickly cleared with Vitamin D - Meta-analysis Feb 2019
- Catching Tuberculosis from family member 2 X more likely if low vitamin D – meta-analysis Dec 2018
- Tuberculosis in children 1.7 X more likely if low vitamin D – meta-analysis Aug 2018
- Low vitamin D is a risk factor for tuberculosis – meta-analysis Dec 2016
- Tuberculosis 1.3 times more likely if poor Vitamin D Receptor – meta-analysis Oct 2016
- Tuberculosis 4.5X more likely if vitamin D less than 10 nanogram – meta-analysis May 2015
- Tuberculosis, genes and vitamin D – Meta-Analysis Dec 2013
- TB associated with low vitamin D in a review and meta-analysis – 2008
- TB and vitamin D updated review and meta-analysis – plays a role Jan 2010
From Press Release
10.0 million people developed active tuberculosis worldwide in 2017,
Multi-drug resistant (MDR) TB.occurred in ~500,000 cases. (5%)
- "Lead researcher Professor Adrian Martineau from Queen Mary University of London said: "Multi-drug resistant TB is on the rise globally. It's notoriously difficult to treat, and it carries a much worse prognosis than standard TB."
- "By adding vitamin D to antibiotic treatment, we can boost the immune system to help the body to clear TB bugs, rather than relying on antibiotics on their own to kill the bacteria directly"
Download the PDF from Sci-Hub via VitaminDWiki
Vitamin D dosing varied widely: daily, weekly, infrequently, and single
Background Randomised controlled trials (RCTs) of adjunctive vitamin D in pulmonary tuberculosis (PTB) treatment have yielded conflicting results. Individual participant data (IPD) meta-analysis could identify factors explaining this variation.
Methods We meta-analysed IPD from RCTs of vitamin D in patients receiving antimicrobial therapy for PTB. Primary outcome was time to sputum culture conversion. Secondary outcomes were time to sputum smear conversion, mean 8-week weight and incidence of adverse events. Pre-specified sub-group analyses were done according to baseline vitamin D status, age, sex, drug-susceptibility, HIV status, extent of disease, and vitamin D receptor genotype.
Results IPD were obtained for 1850 participants in 8 studies. Vitamin D did not influence time to sputum culture conversion overall (aHR 1.06, 95% CI 0.91–1.23), but it did accelerate sputum culture conversion in participants with multidrug-resistant PTB (aHR 13.44, 95% CI 2.96–60.90); no such effect was seen in those whose isolate was sensitive to rifampicin and/or isoniazid (aHR 1.02, 95% CI 0.88–1.19; Pinteraction=0.02). Vitamin D accelerated sputum smear conversion overall (aHR 1.15, 95% CI 1.01–1.31), but did not influence other secondary outcomes.
Conclusions Vitamin D did not influence time to sputum culture conversion overall, but it accelerated sputum culture conversion in patients with multidrug-resistant PTB.